aptose biosciences is a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (aml), high-risk myelodysplastic syndromes (mds) and other hematologic malignancies. based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways. aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. in the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies. cg026806 (cg’806) is a highly potent first-in-class pan-flt3/btk inhibitor. this small molecule therapeutic agent, exhibits a picomolar ic50 toward the fms-like tyrosine kinase 3 with the internal tandem duplication (flt
Company profile
Ticker
APTO, APS
Exchange
Website
CEO
William Rice
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.), IMUTEC PHARMA INC, LORUS THERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
Aptose Biosciences U.S. Inc. • NuChem Pharmaceuticals Inc. ...
APTO stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5 Apr 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
Aptose Reports Results for the Fourth Quarter and Full Year 2023
26 Mar 24
8-K
Regulation FD Disclosure
18 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1 Mar 24
8-K
Regulation FD Disclosure
31 Jan 24
8-K
Entry into a Material Definitive Agreement
29 Jan 24
424B4
Prospectus supplement with pricing info
26 Jan 24
8-K
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
26 Jan 24
EFFECT
Notice of effectiveness
26 Jan 24
Transcripts
APTO
Earnings call transcript
2023 Q4
26 Mar 24
APTO
Earnings call transcript
2023 Q3
9 Nov 23
APTO
Earnings call transcript
2023 Q2
10 Aug 23
APTO
Earnings call transcript
2023 Q2
10 Aug 23
APTO
Earnings call transcript
2023 Q1
8 May 23
APTO
Earnings call transcript
2023 Q1
8 May 23
APTO
Earnings call transcript
2022 Q4
23 Mar 23
APTO
Earnings call transcript
2022 Q4
23 Mar 23
APTO
Earnings call transcript
2022 Q3
1 Nov 22
APTO
Earnings call transcript
2022 Q3
1 Nov 22
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 15.72 mm | 15.72 mm | 15.72 mm | 15.72 mm | 15.72 mm | 15.72 mm |
Cash burn (monthly) | (no burn) | 1.02 mm | 3.89 mm | 4.22 mm | 3.51 mm | 3.67 mm |
Cash used (since last report) | n/a | 7.01 mm | 26.68 mm | 28.91 mm | 24.06 mm | 25.12 mm |
Cash remaining | n/a | 8.71 mm | -10.96 mm | -13.19 mm | -8.34 mm | -9.40 mm |
Runway (months of cash) | n/a | 8.5 | -2.8 | -3.1 | -2.4 | -2.6 |
Institutional ownership, Q2 2023
95.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 23 |
Opened positions | 7 |
Closed positions | 14 |
Increased positions | 0 |
Reduced positions | 14 |
13F shares | Current |
---|---|
Total value | 1.70 bn |
Total shares | 14.95 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Wilson Donald R. Jr. | 8.89 mm | $23.39 mm |
Fletcher Aaron G.L. | 5.11 mm | $6.13 mm |
DRW Securities | 592.83 k | $2.75 mm |
Nantahala Capital Management | 146.23 k | $678.52 mm |
Carlson Capital L P | 106.67 k | $494.93 mm |
MS Morgan Stanley | 47.08 k | $218.46 mm |
GS Goldman Sachs | 35.47 k | $164.59 mm |
Voss Capital | 14.63 k | $67.90 mm |
USB U.S. Bancorp. | 2.02 k | $9.37 mm |
WFC Wells Fargo & Co. | 1.71 k | $7.94 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Feb 24 | Whitehead Warren | Director Stock Options Common Shares | Grant | Acquire A | No | No | 1.97 | 3,333 | 6.57 k | 3,333 |
5 Feb 24 | Burger Denis R | Director Stock Option Common Shares | Grant | Acquire A | No | No | 2 | 3,333 | 6.67 k | 3,333 |
5 Feb 24 | Ashe Carol Gail | Director Stock Option Common Shares | Grant | Acquire A | No | No | 2 | 3,333 | 6.67 k | 3,333 |
5 Feb 24 | Vincent Mark D. | Director Stock Option Common Shares | Grant | Acquire A | No | No | 1.97 | 3,333 | 6.57 k | 3,333 |
5 Feb 24 | Platzer Erich | Director Stock Option Common Shares | Grant | Acquire A | No | No | 2 | 3,333 | 6.67 k | 3,333 |
News
Piper Sandler Maintains Overweight on Aptose Biosciences, Maintains $5 Price Target
3 Apr 24
HC Wainwright & Co. Maintains Buy on Aptose Biosciences, Maintains $23 Price Target
27 Mar 24
Aptose Biosciences Q4 EPS $(1.44) Beats $(1.59) Estimate
26 Mar 24
Recap: Aptose Biosciences Q4 Earnings
26 Mar 24
Earnings Scheduled For March 26, 2024
26 Mar 24
Press releases
Aptose Reports Results for the Fourth Quarter and Full Year 2023
26 Mar 24
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
18 Mar 24
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
31 Jan 24
Thinking about buying stock in Cipher Mining, SoundHound AI, Cellectar Biosciences, Bitdeer Technologies, or Aptose Biosciences?
26 Jan 24
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
26 Jan 24